Serenex Company Profile

Serenex is an integrated oncology-focused drug discovery and development company. Our mission is to improve the lives of cancer patients by developing proprietary therapeutic and supportive care products. Our most advanced program, SNX-1012, is a product for chemotherapy and radiation-induced oral mucositis. This is scheduled to complete Phase 2 trials in Q1 2007. Our most advanced preclinical-stage program, SNX-5422, is a novel small molecule inhibitor of Heat Shock Protein 90. Hsp90 is a chaperone protein for a variety of oncogenic proteins (such as Her2 and Raf) and their downstream signaling molecules (such as Akt and Erk). SNX-5542 is scheduled to begin clinical trials in Q1 2007.

Location

323 Foster StreetDurhamNorth Carolina27701United States of America

Contact

Phone: (919) 281 6001Fax: (919) 281 6050Email: info@serenex.com

News Articles
[0 Results]

None

Drugs and Medications
[0 Results]

None

PubMed Articles
[0 Results]

None

Clinical Trials
[0 Results]

Serenex is an integrated oncology-focused drug discovery and development company. Our mission is to improve the lives of cancer patients by developing proprietary therapeutic and supportive care produ...

Head and neck cancersCancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area.
Mouth cancers (oral cancers) - Mouth cancer can develop on the lip, the tongue, the floor...